Sippican Capital Advisors Has $2.25 Million Stock Holdings in Pfizer Inc. $PFE

Key Points

• Sippican Capital Advisors increased its investment in Pfizer by 37.4%, holding 92,912 shares valued at approximately $2.25 million, which makes up about 1.6% of their investment portfolio.
• Pfizer announced a quarterly dividend of $0.43 per share, yielding approximately 6.9% annually, with the ex-dividend date set for November 7.
• Analysts have mixed ratings on Pfizer's stock, with an average target price of $28.35, and numerous recent adjustments to price targets by various research firms.

Sippican Capital Advisors increased its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 37.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 92,912 shares of the biopharmaceutical company's stock after acquiring an additional 25,285 shares during the quarter. Pfizer comprises about 1.6% of Sippican Capital Advisors' investment portfolio, making the stock its 20th largest position. Sippican Capital Advisors' holdings in Pfizer were worth $2,252,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. Brighton Jones LLC increased its holdings in Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock valued at $17,677,000 after purchasing an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC increased its holdings in Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock valued at $498,000 after purchasing an additional 2,087 shares during the last quarter. GAMMA Investing LLC increased its holdings in Pfizer by 69.0% in the first quarter. GAMMA Investing LLC now owns 63,131 shares of the biopharmaceutical company's stock valued at $1,600,000 after purchasing an additional 25,785 shares during the last quarter. NorthCrest Asset Manangement LLC increased its holdings in Pfizer by 16.5% in the first quarter. NorthCrest Asset Manangement LLC now owns 45,391 shares of the biopharmaceutical company's stock valued at $1,150,000 after purchasing an additional 6,440 shares during the last quarter. Finally, Everhart Financial Group Inc. increased its holdings in Pfizer by 29.9% in the first quarter. Everhart Financial Group Inc. now owns 14,528 shares of the biopharmaceutical company's stock valued at $368,000 after purchasing an additional 3,347 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on PFE. Weiss Ratings reiterated a "hold (c-)" rating on shares of Pfizer in a report on Wednesday. Citigroup upped their price objective on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Wall Street Zen downgraded Pfizer from a "buy" rating to a "hold" rating in a report on Sunday, September 28th. Bank of America increased their price target on Pfizer from $28.00 to $30.00 and gave the stock a "neutral" rating in a report on Friday, October 3rd. Finally, Morgan Stanley dropped their price target on Pfizer from $33.00 to $32.00 and set an "equal weight" rating on the stock in a research report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $28.35.

Pfizer Trading Down 1.7%

NYSE PFE opened at $24.81 on Friday. The firm has a market cap of $141.03 billion, a P/E ratio of 13.19, a P/E/G ratio of 0.81 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The stock's 50-day moving average is $24.86 and its 200-day moving average is $24.13. Pfizer Inc. has a one year low of $20.92 and a one year high of $29.82.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.Pfizer's revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer's dividend payout ratio (DPR) is currently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.